J & J’s guselkumab (trade name: Tremfya) has recently been applied for marketing in China, which is called the “best psoriasis drug” owing to its separately defeating adalimumab and secukinumab in the head-to-head studies, with sales reaching USD544 million in 2018, showing the potential of becoming a blockbuster.
